1. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 2): II43–7.
2. IBS Management Guidelines 2009. What Your Doctor Knows About Treating IBS. By B.B.Bolen, Ph. D. About. com Guide Updated December 05, 2011.
3. Celebi S, Acik Y, Deveci SE et al. Epidemiological features of irritable bowel syndrome in a Turkish urban society. J Gastroenterol Hepatol 2004; 19 (7): 738–43.
4. Hungin AP, Chang L, Locke GR et al. Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365–75.
5. Agreus L, Talley NJ, Svardsudd K et al. Identifying dyspepsia and irritable bowel syndrome: The value of pain or discomfort, and bowel habit descriptors. Scand J Gastroenterol 2000; 35: 142–51.
6. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377–90.
7. Яковенко А.В., Иванов А.Н., Прянишникова А.С. и соавт. Патогенетические подходы в лечении синдрома раздраженного кишечника. Лечащий врач. 2001; 7.
8. Spiegel BM, Farid M, Esrailian E et al. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010; 105 (4): 848–58.
9. Lembo AJ, Neri B, Tolley J et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. AlimentPharmacol Ther 2009; 29: 834–42.
10. Riedl A, Schmidtmann M, Stengel A et al. Somatic comorbidities of irritable bowel syndrome: A systematic analysis. J Psychosom Res 2008; 64: 573–82.
11. Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190–2.
12. Keohane J, O'Mahony C, O'Mahony L et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease. A real association or reflection of occult inflammation. Am J Gastroenterol 2010; doi: 10.1038/ajg.2010.156
13. Thabane M, Kottachchi D, Marshall JK. Systematic review and meta-analysis: Incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535–44.
14. Chadwick V, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778–83.
15. Niaz SK, Sandrasegaran K, Renny FH, Jones BJ. Postinfective diarrhoea and bile acid malabsorption. JR Coll Physicians Lond 1997; 31: 53–6.
16. Ford AC, Spiegel BMR, Talley NJ, Moayyedi P. Small intestinal bacterial over-growth in irritable bowel syndrome: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 1279–86.
17. McKernan DP, Gaszner G, Quigley EM et al. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33(9): 1045–52, 1365–2036.
18. Kalantar JS, Locke GR, Zinsmeister AR et al. Familial aggregation of irritable bowel syndrome: A prospective study. Gut 2003; 52: 1703–7.
19. Atkinson W, Lockhart S, Whorwell PJ et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34–43.
20. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 2004; 141 (8): 1285–93.
21. Read NW, Gwee KA. The importance of 5-hydroxytryptamine receptors in the gut. Pharmacol Ther 1994; 62 (1–2): 159–73.
22. Ford AC, Talley NJ, Schoenfeld PS et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58 (3): 367–78.
23. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther 2010; 32 (7): 1221–33.
24. National Collaborating Centre for Nursing and Supportive Care. Irritable bowel syndrome in adults. Diagnosis and management of irritable bowel syndrome in primary care. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Feb. 881p. (Clinical guideline; no. 61).
25. Wesdorp ICE. The central role of Ca++ as mediator of gastrointestinal motility. In: Calcium antagonism & Gastrointestinal motility. Experta Medica 1989; p. 20–7.
26. McCallum RW. The role of calcium and calcium antagonism in motility disorders of the gastrointestinal tract. In: Calcium antagonism & Gastrointestinal motility. Experta Medica 1989; p. 28–31.
27. Awad RA, Cordova VH, Dibildox M et al. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome. Acta Gastroenterol Latinoam 1997; 27 (4): 247–51.
28. Wittmann T, Fehér A, Rosztóczy A, Jánosi J. Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome. Orv Hetil 1999; 140 (9): 469–73.
29. Ford AC et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313.
30. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8 (5): 499–510.
31. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16 (5): 547–53.
32. Spiller R et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770–98.

А.А.Самсонов1, Е.Ю.Плотникова2, С.А.Кочетов1 

1 ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФ;
2 ГБОУ ВПО КемГМА Минздрава РФ